Search research articles
Contact Us
Filters
Showing results (411-420 of 484) with videos related to
Page
of 49
Sort By:
Rheumatology (Oxford, England)
|
February 24, 2026
A randomised open label pilot trial comparing mycophenolate mofetil with no immunosuppression in limited cutaneous systemic sclerosis (MINIMISE-Pilot)
Christopher P Denton, Philip Yee, Medha Kanitkar, et al.
Arthritis and Rheumatism
|
November 30, 2006
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma
Rachel K Hoyles, Ross W Ellis, Jessica Wellsbury, et al.
Annals of the Rheumatic Diseases
|
October 26, 2017
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)
Dinesh Khanna, Christopher P Denton, Celia J F Lin, et al.
Arthritis and Rheumatism
|
December 30, 2006
Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192
Christopher P Denton, Peter A Merkel, Daniel E Furst, et al.
Journal of Scleroderma and Related Disorders
|
June 18, 2026
Expert recommendations for the management of refractory gastroesophageal reflux disease in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) Gastrointestinal "Ad hoc committee"
Michael Hughes, Anna Lo Cricchio, Maria Cristina De Santis, et al.
Journal of Scleroderma and Related Disorders
|
August 25, 2025
Treatment recommendations for the systemic pharmacological treatment of systemic sclerosis digital ulcers: Results from the World Scleroderma Foundation Ad Hoc Committee
Nancy Maltez, Laura Ross, Murray Baron, et al.
The Lancet. Respiratory Medicine
|
January 7, 2021
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial
Kristin B Highland, Oliver Distler, Masataka Kuwana, et al.
Respirology (Carlton, Vic.)
|
December 18, 2020
Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression
Carmel J W Stock, Rachel K Hoyles, Cecile Daccord, et al.
Rheumatology (Oxford, England)
|
May 17, 2024
Native myocardial T1 and right ventricular size by CMR predict outcome in systemic sclerosis-associated pulmonary hypertension
Daniel S Knight, Ruta Virsinskaite, Nina Karia, et al.
Annals of the Rheumatic Diseases
|
October 2, 2020
Genomic Risk Score impact on susceptibility to systemic sclerosis
Lara Bossini-Castillo, Gonzalo Villanueva-Martin, Martin Kerick, et al.
Page
of 49
Search research articles
Search
Showing results (411-420 of 484) with videos related to
Sort By:
Page
of 49
Rheumatology (Oxford, England)
|
February 24, 2026
A randomised open label pilot trial comparing mycophenolate mofetil with no immunosuppression in limited cutaneous systemic sclerosis (MINIMISE-Pilot)
Christopher P Denton, Philip Yee, Medha Kanitkar, et al.
Arthritis and Rheumatism
|
November 30, 2006
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma
Rachel K Hoyles, Ross W Ellis, Jessica Wellsbury, et al.
Annals of the Rheumatic Diseases
|
October 26, 2017
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)
Dinesh Khanna, Christopher P Denton, Celia J F Lin, et al.
Arthritis and Rheumatism
|
December 30, 2006
Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192
Christopher P Denton, Peter A Merkel, Daniel E Furst, et al.
Journal of Scleroderma and Related Disorders
|
June 18, 2026
Expert recommendations for the management of refractory gastroesophageal reflux disease in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) Gastrointestinal "Ad hoc committee"
Michael Hughes, Anna Lo Cricchio, Maria Cristina De Santis, et al.
Journal of Scleroderma and Related Disorders
|
August 25, 2025
Treatment recommendations for the systemic pharmacological treatment of systemic sclerosis digital ulcers: Results from the World Scleroderma Foundation Ad Hoc Committee
Nancy Maltez, Laura Ross, Murray Baron, et al.
The Lancet. Respiratory Medicine
|
January 7, 2021
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial
Kristin B Highland, Oliver Distler, Masataka Kuwana, et al.
Respirology (Carlton, Vic.)
|
December 18, 2020
Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression
Carmel J W Stock, Rachel K Hoyles, Cecile Daccord, et al.
Rheumatology (Oxford, England)
|
May 17, 2024
Native myocardial T1 and right ventricular size by CMR predict outcome in systemic sclerosis-associated pulmonary hypertension
Daniel S Knight, Ruta Virsinskaite, Nina Karia, et al.
Annals of the Rheumatic Diseases
|
October 2, 2020
Genomic Risk Score impact on susceptibility to systemic sclerosis
Lara Bossini-Castillo, Gonzalo Villanueva-Martin, Martin Kerick, et al.
Page
of 49